Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer.
The aim of the present study was to investigate the efficacy of paclitaxel following a first-line cisplatin regimen in patients with metastatic bladder cancer. The present study retrospectively evaluated the clinical effects and toxicities of second-line paclitaxel regimens following first-line cisplatin treatment in metastatic bladder cancer. A total of 42 patients with progressing metastatic urothelial bladder cancer following cisplatin-based chemotherapy were enrolled. The patients received weekly treatment with paclitaxel (80 mg/m2) with a median duration of 3 months. The overall response rate, disease control rate and median progression free survival were 9.5, 45.2 and 6.4 months, respectively. Weekly paclitaxel was well-tolerated with rare grade III or IV toxicities. Second-line weekly paclitaxel treatment following first-line cisplatin-based chemotherapy is an effective and well-tolerated regimen in urothelial metastatic bladder cancer.
Medical Oncology Clinic, Jules Bordet Institute, 1000 Brussels, Belgium.
Spyridon
S
Sideris
Department of Urology, Jules Bordet Institute, 1000 Brussels, Belgium.
Fouad
F
Aoun
Data Center, Université Paris XII, 94010 Créteil, France.
Marc
M
Zanaty
Medical Oncology Clinic, University Hospital of Erasme, 1070 Brussels, Belgium.
Nieves Chanza
NC
Martinez
Medical Oncology Clinic, Jules Bordet Institute, 1000 Brussels, Belgium.
Sofia
S
Latifyan
Medical Oncology Clinic, Jules Bordet Institute, 1000 Brussels, Belgium.
Ahmad
A
Awada
Medical Oncology Clinic, Jules Bordet Institute, 1000 Brussels, Belgium.
Thierry
T
Gil
neutrophil to lymphocyte ratio; overall survival; paclitaxel; toxicity; urothelial cancer